Identification of Serum Amyloid A as a Biomarker to Distinguish Prostate Cancer Patients with Bone Lesions
Background: Prostate cancer has a propensity to metastasize to the bone. Currently, there are no curative treatments for this stage of the disease. Sensitive biomarkers that can be monitored in the blood to indicate the presence or development of bone metastases and/or response to therapies are
Screening, prevention, detection, and treatment of cancer therapy-induced bone loss in patients with breast cancer.
Purpose/Objectives: To identify protocols to screen, detect, prevent, and treat cancer therapy-induced bone loss resulting in osteoporosis in patients with breast cancer. Data Sources: Published books and articles. Data Synthesis: Normal bone remodeling is affected by hormonal stimulation. Breast
The Markers of Bone Turnover in Patients with Lung Cancer
Introduction: Bone metastases may change the primary treatment modality, especially if the bone is the only site of metastasis in patients considered to be in the early stage of lung cancer. It is usually diagnosed by imaging techniques. However, the diagnostic yields of imaging methods are
Bone marrow transplants: from Chernobyl to cancer therapy.
Bone Marrow Transplants: From Chernobyl to Cancer Therapy It was one year ago this month that clouds of radioactivedust and smoke settled over the cities of Chernobyl and Kiev in the Soviet Union after a nuclear rezctor exploded. Immediately, Russian and American doctors rushed to perform a
Managing Bone Loss in Cancer Patients
Cancer patients are at a higher risk for developing osteoporosis due to accelerated loss in bone density associated with many anticancer treatments. There are a variety of hormonal and non-hormonal treatments that may promote bone loss by inducing hypogonadism, which increases bone resorption and
Glutamine supplementation in cancer patients receiving bone marrow transplantation and high dose chemotherapy
Glutamine Supplementation in Cancer Patients Receiving Bone Marrow Transplantation and High Dose Chemotherapy1,2 ABSTRACT Glutamine supplementation of enteral and parenteral nutrition support has received increased attention in the research community over the past decade. Glutamine may become a
Zoledronic acid : bisphosphonate for prostate cancer/bone metastases. .
Prostate cancer is most likely to metastasize to the bone. Approximately 50% to 70% of prostate cancer patients develop skeletal metastases and associated bone pain (Buckwalter & Brandser, 1997). Most men with advanced disease who die of prostate cancer have some evidence of bone metastases.
New Data Show Zometa Significantly Improved Bone Mineral Density in Breast Cancer Patients Receiving Adjuvant Therapy.
Bone Loss Is A Well-Documented Side Effect In Breast Cancer Patients Treated With Aromatase Inhibitors EAST HANOVER, N.J., May 15 /PRNewswire/ - Zometa(R) (zoledronic acid) injection, an intravenous bisphosphonate administered to more than one million patients worldwide, was shown to inhibit
Breast Cancer Roulette; For women with aggressive tumors, bone marrow transplants have been regarded as the best hope for a cure. But new studies indicate that this life-threatening procedure may be no better than conventional treatment.
Since the early 1990s bone marrow transplants have been regarded as the best of treatments and the worst of treatments for aggressive or advanced breast cancer. Thousands of desperate women, clinging to a glimmer of hope that the procedure might cure them-or buy them significantly more time-have
Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy.
Purpose/Objectives: To test the effects of aerobic and resistance exercise on changes in bone mineral density (BMD) in women newly diagnosed with stage I-III breast cancer receiving chemotherapy. Design: Randomized clinical trial. Setting: Two National Cancer Institute-designated cancer centers in
